Amarantus Bioscience Holdings Inc (AMBS)

[tsuguy]

Makes sense when you read Gerald's letter from August 6:

LymPro

Becton Dickinson ("BD") has agreed to become the development laboratory for LymPro Test ®, allowing the Company to leverage BD's team of world class scientists with deep expertise in flow-based assay execution and implementation. We are using BD's reagents in our development, as they are manufactured to the high standards necessary to meet the mass-scale distribution needed for LymPro to reach the over 400,000 individuals diagnosed and 5 million people living with Alzheimer's each year. Under the terms of the agreement, the Company retains full control and ownership over all intellectual property newly developed from all activities currently underway. We believe that leveraging BD's development expertise will significantly differentiate Amarantus' LymPro from competitors in the Alzheimer's blood biomarker space by not only reproducing high sensitivity and specificity published in peer-reviewed literature, but most importantly having the capabilities to make the assay robustly reproducible through a strong analytical performance package, as will be required to achieve deep market penetration once commercialized. We are working closely with our team of advisors to ensure that the work being conducted at BD will be of the highest standards.

Looks like the advisors think this the test is almost done and ready for commercialization!